Navidea Announces EMA Continues Marketing Authorization Application Review for Lymphoseek
December 19, 2013 at 19:34 PM EST
Navidea Biopharmaceuticals (NYSE: NAVB ) announced today that the European Medicines Agency (EMA) has provided updated Day 180 feedback and has elected to continue the assessment of the
